期刊
NATURE REVIEWS CARDIOLOGY
卷 15, 期 2, 页码 212-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrcardio.2017.212
关键词
-
资金
- Amarin
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Chiesi
- Eisai
- Ethicon
- Forest Laboratories
- Ironwood
- Ischemix
- Lilly
- Medtronic
- Pfizer
- Roche
- Sanofi Aventis
- Medicines Company
In 2017, several high-impact studies in thrombosis were published. Refinements were made in the optimal therapy for patients with stable atherosclerosis or with atrial fibrillation undergoing percutaneous coronary intervention. Risk scores to determine duration of antiplatelet therapy were developed. The potential risk of subclinical valve leaflet thrombosis was identified.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据